Safety and Feasibility of Third-Party Cytotoxic T Lymphocytes for High-Risk Patients with Covid-19.
Grosso D, Wagner JL, O'Connor A, Keck K, Huang Y, Wang ZX, Mehler H, Leiby B, Flomenberg P, Gergis U, Nikbakht N, Morris M, Karp JK, Peedin A, Flomenberg N.
Grosso D, et al. Among authors: wang zx.
Blood Adv. 2024 Jun 17:bloodadvances.2024013344. doi: 10.1182/bloodadvances.2024013344. Online ahead of print.
Blood Adv. 2024.
PMID: 38885482